Spots Global Cancer Trial Database for SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
Official Title: Effect of SBRT Combined With Osimertinib Compared With Osimertinib Alone for Stage IV Non-small Cell Lung Cancer
Study ID: NCT05583409
Conditions
Study Description
Brief Summary: This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China, Wuhan, Hubei, China
Contact Details
Name: Li Zhang, MD,PhD
Affiliation: Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
